Surgical and clinical management of a patient with Glanzmann thrombasthenia: A case report

被引:0
|
作者
Gomes, MF
de Melo, RM
Plens, G
Pontes, EM
Silva, MM
da Rocha, JC
机构
[1] UNESP, Fac Odontol Sao Jose Campos, Dept Biociencias & Diagnost Bucal, Sao Jose Campos Dent Sch, BR-12245000 Sao Jose Dos Campos, SP, Brazil
[2] Biosci Ctr Special Hlth Care Needs, Sao Paulo, Brazil
[3] Special Hlth Care Needs Assoc, Sao Paulo, Brazil
[4] HEMOVIDA Sao Jose Campos, Hematol & Hemotherapy Serv, Sao Jose Dos Campos, SP, Brazil
[5] Oncol Pediat Grp GRP, Sao Jose Dos Campos, SP, Brazil
[6] UNESP, Sao Jose Campos Dent Sch, Dept Pediat & Social Dent & Special Care Treatmen, BR-12245000 Sao Jose Dos Campos, SP, Brazil
[7] UNESP, Sao Jose Campos Dent Sch, Study Ctr, BR-12245000 Sao Jose Dos Campos, SP, Brazil
来源
QUINTESSENCE INTERNATIONAL | 2004年 / 35卷 / 08期
关键词
clinical management; dental extraction; Glanzmann thrombasthenia; IIb/IIIa glycoprotein complex; odontologic management;
D O I
暂无
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
A 6-year-old girl with Glanzmann thrombasthenia presented with caries and periapical lesions in the primary mandibular second molars and moderate gingivitis of the maxillary and mandibular anterior teeth. Dental extraction was recommended, and before every surgical intervention, the patient underwent platelet-concentrate transfusion to prevent hemorrhage. Epsilon aminocaproic acid was administered 6 hours before, and 48 hours after every dental procedure to prevent bleeding. In this case, treatment was effective in the prevention of hemorrhagic complications, during the required dental procedures.
引用
收藏
页码:617 / 620
页数:4
相关论文
共 50 条
  • [32] Recombinant activated factor VII combined with desmopressin in preventing bleeding from dental extraction in a patient with Glanzmann's thrombasthenia
    Lombardo, VT
    Sottilotta, G
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2006, 12 (01) : 115 - 116
  • [33] Modeling Glanzmann thrombasthenia using patient specific iPSCs and restoring platelet aggregation function by CD41 overexpression
    Hu, Liang
    Du, Lili
    Zhao, Yan
    Li, Wen
    Ouyang, Qi
    Zhou, Di
    Lu, Guangxiu
    Lin, Ge
    STEM CELL RESEARCH, 2017, 20 : 14 - 20
  • [34] Glanzmann's thrombasthenia (defective platelet integrin αIIb-β3: proposals for management between evidence and open issues
    Di Minno, Giovanni
    Coppola, Antonio
    Di Minno, Matteo Nicola Dario
    Poon, Man-Chiu
    THROMBOSIS AND HAEMOSTASIS, 2009, 102 (06) : 1157 - 1164
  • [35] Novel homozygous frameshift mutation of ITGB3 in the Glanzmann thrombasthenia patient with abnormal bone metabolism and congenital bone defects
    Yujiao Luo
    Nina Guo
    Yewei Wang
    Ji Li
    Orphanet Journal of Rare Diseases, 20 (1)
  • [36] A β3 Asp217→Val substitution in a patient with variant Glanzmann Thrombasthenia severely affects integrin αIIBβ3 functions
    D'Andrea, Giovanna
    Bafunno, Valeria
    Del Vecchio, Luigi
    Amoriello, Aldo
    Morabito, Paolo
    Vecchione, Gennaro
    Grandone, Elvira
    Margaglione, Maurizio
    BLOOD COAGULATION & FIBRINOLYSIS, 2008, 19 (07) : 657 - 662
  • [37] Insertion of a C in the exon 28 of integrin αIIb gene leading to a frameshift mutation is responsible for Glanzmann thrombasthenia in a Japanese case
    Hayashi, T
    Tanaka, S
    Hori, Y
    Terada, C
    Ueda, Y
    Tani, Y
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (03) : 489 - 496
  • [38] Triple jeopardy: A case of Glanzmann's thrombasthenia with anti-GPIIb-IIIa antibodies and HPA incompatibility resulting in stillbirth
    Soni, Puja
    Mantri, Shruti
    Prabhudesai, Aniket
    Patil, Rucha
    Shanmukhaiah, Chandrakala
    Shetty, Shrimati
    THROMBOSIS RESEARCH, 2019, 181 : 141 - 144
  • [39] Iron deficiency anemia and bleeding management in pediatric patients with Bernard-Soulier syndrome and Glanzmann Thrombasthenia: A single-institution analysis
    Lee, Annika
    Maier, Cheryl L.
    Batsuli, Glaivy
    HAEMOPHILIA, 2022, 28 (04) : 633 - 641
  • [40] Pyelolithotomy in a patient with Glanzmann thrombasthenia and antiglycoprotein IIb/IIIa antibodies:: the shortest possible duration of treatment with recombinant activated factor VII and platelet transfusions
    Devecioglu, Ö
    Ünüvar, A
    Anak, S
    Bilge, I
    Ander, H
    Ziylan, O
    TURKISH JOURNAL OF PEDIATRICS, 2003, 45 (01) : 64 - 66